Clinical Report: Systematic Review of Digital Technologies and Biomarkers for Cognitive Assessment

Overview

This systematic review evaluates digital cognitive assessment tools and biomarkers, contrasting traditional neuropsychological tests with innovative digital approaches.

Background

The rising prevalence of dementia, particularly in South Korea, necessitates effective cognitive assessment tools. Traditional screening methods face limitations in accessibility, sensitivity, and scalability.

Data Highlights

No numerical data or trial data was provided in the source material.

Key Findings

• Digital cognitive assessment tools provide automated evaluations.
• Digital biomarkers capture continuous data for cognitive changes.
• Traditional assessments are time-consuming and require trained personnel.
• Speech and language features can indicate cognitive decline.
• Motor and behavioral patterns have predictive value for cognitive impairment.

Clinical Implications

The integration of digital cognitive assessment tools and biomarkers could enhance early detection and monitoring of cognitive decline.

Conclusion

Digital technologies and biomarkers address limitations of traditional methods.

Related Resources & Content

1. npj Digital Medicine, 2026 -- Wearable Sensors for Continuous Monitoring of Cognitive and Emotional Well-Being: Exploring Digital Biomarkers for Brain Health
2. npj Digital Medicine, 2026 -- Systematic Evaluation of Wearable EEG Technology for Identifying Mild Cognitive Impairment
3. npj Digital Medicine, 2026 -- Digital Cognitive Evaluation for Aging and Dementia via the Oxford Cognitive Testing Portal (OCTAL)
4. Criteria for Diagnosis and Staging of Alzheimer's Disease | alz.org
5. Frontiers in Digital Health — Evaluating Verbal and Spatial Memory Using Smartphone Technology
6. Updated appropriate use criteria for amyloid and tau PET
7. ACR Appropriateness Criteria® Dementia: 2024 Update
8. Criteria for Diagnosis and Staging of Alzheimer's Disease | alz.org
9. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease - PMC
10. Association Between Amyloid PET and Change in Care of Patients With Mild Cognitive Impairment or Dementia
11. Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study - PMC
12. Diagnostic accuracy of phosphorylated tau217 in detecting Alzheimer's disease pathology among cognitively impaired and unimpaired: A systematic review and meta‐analysis - Khalafi - 2025 - Alzheimer's & Dementia - Wiley Online Library
13. Clinical Practice Guideline: Blood-Based Biomarkers in Specialty Care | Alzheimer's Association®
14. Passive digital health technologies for Alzheimer’s disease screening and diagnosis: a systematic review | npj Digital Medicine
15. Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies: A systematic review - Porta‐Mas - 2025 - Alzheimer's & Dementia - Wiley Online Library
16. Diagnostic utility of speech-based biomarkers in mild cognitive impairment: a systematic review and meta-analysis | Age and Ageing | Oxford Academic